John Mascarenhas, MD, discusses the results of the PACIFICA trial at the 2022 American Society of Hematology Annual Meeting. Whole blood mutation allele frequency had only weak prognostic value in certain patients with polycythemia vera. Several factors were independently associated with arterial thrombotic events in patients with myeloproliferative neoplasms. Symptom-related quality of life is linked with the type of cytoreductive treatment used for MPNs. TP53 and complex karyotype are very high-risk factors in patients with myelofibrosis undergoing HSCT. The combination of ruxolitinib and pegylated IFNα2a showed significant reductions in spleen length. BMS-986158 combined with ruxolitinib or fedratinib reduced spleen volume in patients with myelofibrosis. Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis. The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera. Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis. Long-term follow-up results of a phase II study of ruxolitinib in patients with MPNs were presented at the 2022 ASH Meeting. New data support the use of ropeginterferon alfa-2b therapy in patients with low-risk or high-risk PV, An analysis of patients with MF found that the combination of navitoclax and ruxolitinib reduced MF-associated splenomegaly. IFNα2 treatment may help reduce the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...